Patrik Reichl – CEO, CzechInvest
Patrik Reichl, CEO of CzechInvest, the Investment and Business Development Agency under the Ministry of Industry and Trade of the Czech Republic, breaks down the role of the agency in…
The main objective of The Business and Investment Development Agency CzechInvest, is to advise and support existing and new entrepreneurs and foreign investors in the Czech Republic.
Business and Investment Development Agency CzechInvest, is an agency of the Ministry of Industry and Trade. Established in 1992, the agency contributes to attracting foreign investment and developing domestic companies through its services and development programmes. CzechInvest also promotes the Czech Republic abroad and acts as an intermediary between the EU and small and medium-sized enterprises in implementing structural funds in the Czech Republic.
CzechInvest is exclusively authorized to file applications for investment incentives at the competent governing bodies and prepares draft offers to grant investment incentives. Its task is also to provide potential investors current data and information on business climate, investment environment and investment opportunities in the Czech Republic.
CzechInvest´s services (all CzechInvest´s services are free of charge):
full information assistance
tailor-made visits
handling of investment incentives
access to EU structural funds
business properties identification
business infrastructure development
search for potential suppliers/JV/acquisition partners
care for existing investors
Contact
CzechInvest’s Headquarters
Phone: +420 296 342 579
E-mail: fdi@czechinvest.org
Stepanska 15
120 00 Prague
Czech Republic
Patrik Reichl, CEO of CzechInvest, the Investment and Business Development Agency under the Ministry of Industry and Trade of the Czech Republic, breaks down the role of the agency in…
The CEO of CzechInvest elaborates on the significance of the healthcare and life science industry for the Czech Republic’s transition into an industry 4.0. Furthermore, he reviews what the Czech…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here
